The so-called 'cancer shredding' technology uses gene editing technology to modify the genes of cancer cells, and then "shreds" the cancer cells to achieve therapeutic effects.
Nobel laureate and authoritative expert on gene editing at the Gladstone Institute. With the strong support of Dr. Jennifer Doudna, the clinical trial results of translating gene editing (CRISPR) technology into a precision treatment strategy for aggressive and refractory brain tumors (i.e., primary glioblastoma) have shown great application value and development prospects.
Dr. Doudna commented on the innovative application of gene editing technology, which can be applied not only to the treatment of glioblastoma, but also to other highly mutated malignancies.
The method of treating primary glioblastoma using gene editing technology is known as the "cancer crushing" method. Gene editing technology is used to locate and edit specific DNA mutation sequences in tumor cells, thereby killing tumor cells while preserving and not damaging normal cells.
The researchers first needed to perform genetic analysis of the cancer cell lines of recurrent glioblastoma and found that the tumor cells shared certain repeated, non-coding DNA sequences. Using this discovery, gene editing is directed to attack and destroy those cancer cells with mutations. This innovative approach has the potential to be a precise treatment for certain malignant and recurrent tumors.
According to the researchers, there are still some technical challenges to the approach, including the safe and efficient delivery of gene editing into cancer cells and the avoidance of potential off-target effects. In short, the use of gene editing technology to treat diseases that are difficult to deal with but carry gene mutations will have great application value and development prospects.
New progress and application prospects of liquid biopsy for lung cancer
Lung cancer is the deadliest cancer worldwide. Diagnosis of lung cancer requires imaging and pathological tests. In recent years, liquid biopsy has been another minimally invasive method for finding lung cancer-specific biomarkers in body fluids (blood, urine, sputum, and saliva). Cancer cells release cfDNA, ctDNA, exosomes, miRNA, circRNA, CTC, and DNA methylation fragments, which can be used for high-risk screening, clinical diagnosis, prognosis, and prediction of treatment response.
What information should patients and their families know?
How can patients benefit from liquid biopsy monitoring?
What are the details that may be overlooked by doctors?
To compare the benefits and problems of liquid biopsy in early screening in high-risk groups of pancreatic cancer and high-risk groups of lung cancer, welcome to add medical consultant WeChat: GlobalMD2020 to the professional group discussion.
If you or your loved ones are on the road of life,
Inadvertently encountered tumors, cancers, difficult and critical diseases, etc.,
If you need to seek help from international top medical experts, it is recommended that you contact us
——
MORE Health(爱医传递)